Drug repurposing of rimantadine for treatment of cancer.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI:10.4155/ppa-2023-0019
Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos
{"title":"Drug repurposing of rimantadine for treatment of cancer.","authors":"Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos","doi":"10.4155/ppa-2023-0019","DOIUrl":null,"url":null,"abstract":"<p><p>Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"231-236"},"PeriodicalIF":1.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2023-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.

金刚乙胺治疗癌症的药物再利用。
重新利用已批准的药物可以大大节省时间和投资。金刚乙胺是fda批准的预防和治疗甲型流感感染的药物。专利US2021330605描述了金刚烷衍生物金刚乙胺用于治疗黑色素瘤、乳腺癌和头颈部鳞状细胞癌的用途。金刚乙胺抑制黑色素瘤、乳腺癌和头颈部鳞状细胞癌细胞系的增殖,增加注射癌细胞的小鼠的存活率,恢复MHC i类的表达。金刚乙胺有可能成功用于头颈部鳞状细胞癌的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical patent analyst
Pharmaceutical patent analyst PHARMACOLOGY & PHARMACY-
CiteScore
1.80
自引率
0.00%
发文量
22
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信